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ABSTRACT
Background and Purpose: The Jefferson Center for Refugee Health
(JCRH), a component of Jefferson Family Medicine Associates (JFMA), is
the first and largest single provider of refugee health in Philadelphia; over
1,000 refugee primary care visits are provided annually. Refugee patients
are disproportionately affected by latent tuberculosis infection (LTBI)
compared to the general population of the United States; and though
treatment of LTBI is highly effective at reducing conversion to active
tuberculosis (TB), completion rates among the foreign-born are reported to
be less than 50%. To establish baseline LTBI incidence and treatment
completion rates for our refugee population, the JCRH conducted a
retrospective chart review for the time period of 2007-2011. We found that
23.1% of incoming patients to the center had LTBI and among patients
started on LTBI treatment 33.1% completed therapy. Using these rates as a
foundation, we developed an interdisciplinary public health model to
improve care.
Methodology: Our model consists of pharmacy, medicine, nursing, social
work, and community outreach to improve the LTBI completion rates of our
patients. Pharmacy serves as a central point of contact for model
coordination and execution which involves prospective chart review, initial
face-to-face counseling, phone follow up, community monitoring, plus
collaboration with the Philadelphia Department of Health and local
resettlement agency.
Results: Between September 2012 and March 2014, a total of 526 new
patients were seen at the JCRH. Ninety patients were diagnosed with
LTBI, representing an incidence rate of 17%. Seventy –three patients
successfully started LTBI treatment; 44 completed treatment, 29 failed to
complete treatment. The overall completion rate for the 18-month time
period was 60%, representing an almost 2-fold improvement over baseline
rates.

INTRODUCTION
The diagnosis and treatment of LTBI is an effective method for reducing
cases of active TB, however national rates of LTBI completion among
foreign-born in the U.S. is less than 50%.1
The Jefferson Center for Refugee Health conducted a retrospective chart
review for the time period of 2007-2011 to establish our baseline completion
rates. We found that 23.1% of incoming patients to the center had LTBI and
among patients started on treatment 33.1% completed therapy.
Using these baseline rates as a foundation, we developed a unique model
consisting of pharmacy, medicine, nursing, social work, and community
outreach to improve LTBI completion rates in our refugee patients.

METHODS
Visit #

Description
Blood Work

-1

(Resettlement Agency)
Prospective Chart Review
(Medicine/Pharmacy)

0

RESULTS

Initial Refugee Visit
(Medicine/Pharmacy/
Nursing/Social Work)

Process

For the time period 9/1/2012 thru 3/7/2014
• Total number of new patient visits: 526

Quantiferon-TB Gold

Quantiferon-TB Gold, CXR
Quantiferon-TB Gold Results
•If Neg Quant: no further f/u, If Indeterminate PPD placed (nursing visit for read)
•If Pos Quant: CXR ordered
oIf Neg CXR: LTBI treatment to begin at 1 mo f/u visit
oIf Pos CXR: Sputum sample
§
If Neg Sputum sample: LTBI treatment to begin at 1 mo f/u visit
(scheduled by social work)
§
If Pos Sputum sample: refer to Phila Dept of Health (Active TB)

Diagnosed

Started on
LTBI Treatment

Completed
Treatment

Incomplete
Treatment

90*

73

44

29

* 17 patients diagnosed but lost to follow-up prior to initiating treatment
• LTBI incidence rate: 17%
• LTBI treatment completion rate: 60%
Demographics of Patient Who Completed (n=44)

1

Phone
Call

Follow-Up Refugee Visit
(Medicine/Pharmacy/
Nursing/Social Work)

2 weeks after Visit #1

LTBI Treatment Initiated
•Rifampin (Rif) 10mg/kg/day (max 600mg QD) x 4 mos; completion=120 doses within
6 mos.
•Isoniazid (INH) 5mg/kg/day (max 300mg QD) x 6-9 mos; completion: 6 mos
regimen=180 doses within 9 mos;9 mos=270 doses within 12 mos.
Face-to-Face Patient Education (Pharmacy/Medicine)
•Power point presentation of how to have a prescription filled in the U.S.
•Importance of taking medication, what to expect, when to call the HCP
•Reinforce education with written material in native language or pictorial material as
appropriate (will depend on literacy)

Follow up phone call to patient to assess tolerance, symptoms, adherence, answer
any questions patient may have
Pharmacy contacts local pharmacy to confirm refills:
•If no refill noted at pharmacy outbound call to patient to assess
•If refill noted, documented in tracking sheet, then outbound call to patient to assess
tolerance
•If any other issues identified , pharmacy notifies medicine, nursing or social work as
appropriate

Phone
Call

Beginning of month 2 of
treatment

Phone
call

Beginning month 3 of
treatment

Pharmacy repeats procedure described above

Phone
call

Beginning of month 4 of
treatment

Pharmacy repeats procedure described above

Phone
call

End of month 4 of
treatment

Pharmacy contacts local pharmacy to confirm refills:
•If no refill noted, outbound call to patient to assess
•If refill noted, completion documented in patient chart

Medication Counseling Guide:

Gender
n (%)
• Female: 27 (61)
• Male: 17 (39)

Age
(mean, years)
41

Country of Origin
n (%)
•
•
•
•

Bhutan: 31 (70)
Iraq: 7 (16)
Myanmar: 5 (11)
Eritrea: 1 (3)

LTBI Treatment Completion Rates
Pre-Model Implementation

LTBI Treatment Completion Rates
Post-Model Implementation

33.1%

60%

CONCLUSION
Our model increased treatment completion rates almost 2-fold over
baseline. A key limitation to the model was the low success rate of
reaching patients via outbound calls placed 2 weeks after treatment
initiation; as such, earlier contact with the patient and their local pharmacy
is being implemented. In addition, we found engaging local pharmacies to
collect refill history an efficient way to capture adherence as well as create
a source of community support for our patients. An interdisciplinary model
that includes community outreach improves LTBI treatment adherence and
completion in refugee patients.
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